By Gabriel Paijo 
A landmark study conducted by researchers in Brazil has uncovered a critical biological mechanism that explains how pancreatic cancer initiates its spread to other parts of the body at an unexpectedly early stage. Published in the prestigious journal Molecular and Cellular Endocrinology, the research identifies a specific protein, periostin, as a primary driver of perineural invasion—a process where cancer cells infiltrate nearby nerves. This discovery, spearheaded by scientists at the Center for Research on Inflammatory Diseases (CRID), offers a new perspective on why pancreatic ductal adenocarcinoma remains one of the most lethal and treatment-resistant forms of cancer known to modern medicine.
By integrating advanced genomic data with spatial mapping of tumor tissues, the research team demonstrated that pancreatic tumors do not operate in isolation. Instead, they actively "reprogram" the surrounding healthy tissue, turning the stroma—the connective framework of the organ—into a supportive environment for malignancy. This early-stage nerve invasion not only facilitates the rapid metastasis of the disease but also contributes to the intense pain often associated with the condition, marking a significant turning point in the understanding of the tumor microenvironment.
The Global Burden of Pancreatic Adenocarcinoma
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), represents approximately 90% of all pancreatic cancer diagnoses. While it is not the most common form of cancer globally, its clinical impact is disproportionately severe. Unlike many other malignancies where survival rates have seen dramatic improvements over the last three decades, the prognosis for pancreatic cancer remains grim.
Statistically, the disease is characterized by a death rate that nearly mirrors its incidence rate. According to global health data, approximately 510,000 new cases are diagnosed annually, with nearly the same number of deaths reported in the same timeframe. In Brazil, the National Cancer Institute (INCA) estimates roughly 11,000 new cases and 13,000 deaths each year, reflecting the difficulty of managing advanced-stage diagnoses.
Dr. Pedro Luiz Serrano Uson Junior, an oncologist and one of the study’s co-authors, emphasizes the severity of the situation. "It is an exceptionally aggressive cancer. Only about 10% of patients achieve long-term survival, defined as five years post-diagnosis," Uson noted. The primary reason for this high mortality rate is the cancer’s tendency to remain asymptomatic until it has already reached an advanced, non-operable stage.
The Mechanism of Perineural Invasion
The core of the Brazilian study focuses on perineural invasion (PNI), a pathological hallmark of pancreatic cancer where tumor cells surround and eventually penetrate the epineurium, the protective sheath of nerves. PNI is more than just a physical spread; it represents a sophisticated interaction between the nervous system and the tumor.
Nerves serve as a low-resistance pathway—a "highway" of sorts—that allows cancer cells to bypass traditional tissue barriers and travel to distant sites. Because the nervous system is interconnected throughout the abdominal cavity and beyond, PNI provides a direct route for metastasis. Furthermore, the infiltration of cancer cells into the nerve bundles often results in debilitating pain for the patient, which is frequently the symptom that finally leads to a diagnosis.
The researchers found that more than 50% of pancreatic cancer cases already exhibit signs of perineural invasion at the time of the first surgical intervention. However, because these microscopic invasions are often invisible to standard imaging techniques like CT scans or MRIs, they are usually only discovered during a post-operative biopsy of the surgical specimen. By the time PNI is identified, the risk of recurrence is significantly elevated.
Mapping the Tumor Microenvironment: The Active Stroma
For decades, the stroma—the dense, fibrous tissue surrounding a tumor—was viewed by many scientists as a passive "scaffold" or a physical barrier the body built to contain the cancer. The new research from CRID flips this narrative. Using spatial transcriptomics and advanced computational tools, the team analyzed 24 pancreatic cancer samples to map the activity of thousands of genes within individual cells.
The results revealed that the stroma is a highly active and hostile participant in cancer progression. "We were able to integrate data from dozens of samples with extremely powerful resolution," explained Helder Nakaya, a senior researcher at Einstein Israelite Hospital and professor at the University of São Paulo. The analysis showed that the stroma undergoes a process of "remodeling," driven largely by pancreatic stellate cells.
When activated by the presence of a tumor, these stellate cells produce excessive amounts of periostin. Periostin is a protein that normally aids in tissue repair and bone formation, but in the context of a tumor, it becomes a weapon. It alters the extracellular matrix—the "glue" that holds cells together—making it more porous and easier for cancer cells to navigate toward the nerves.
The Desmoplastic Reaction: A Fortress Against Treatment
One of the most significant challenges in treating pancreatic cancer is the "desmoplastic reaction." As the tumor cells and stellate cells interact, they trigger the buildup of dense, fibrous, and scarred tissue. This reaction creates a high-pressure microenvironment that is physically harder than healthy tissue.
This biological "fortress" serves two purposes for the cancer. First, it compresses local blood vessels, reducing the delivery of oxygen and nutrients, which forces the cancer cells to become more resilient and metabolic. Second, and more importantly for clinicians, this dense wall prevents chemotherapy and immunotherapy drugs from penetrating the tumor mass.
"The hardened tissue makes it incredibly difficult for modern medicines to reach their target," Dr. Uson explained. "This protective microenvironment is a primary reason why even the most advanced systemic treatments often fail to produce a durable response in pancreatic cancer patients."
Chronology of the Research and Technological Integration
The study represents a multi-year effort involving several of Brazil’s leading scientific institutions. The work was primarily conducted at the Center for Research on Inflammatory Diseases (CRID), one of the Research, Innovation, and Dissemination Centers (RIDCs) funded by the São Paulo Research Foundation (FAPESP).
The timeline of the research involved several phases:
- Data Acquisition: Researchers utilized high-throughput sequencing and spatial transcriptomics to gather molecular data from patient samples.
- Public Database Mining: In an innovative move, the team integrated their findings with existing public databases, allowing them to validate their observations across a larger cohort of global patients.
- Molecular Mapping: The team focused on the interaction between stellate cells and periostin, specifically looking at how these elements clustered near nerve bundles.
- Validation: The findings were peer-reviewed and published in Molecular and Cellular Endocrinology, establishing a new target for the oncology community.
Carlos Alberto de Carvalho Fraga, who led the research, highlighted that the use of spatial transcriptomics was pivotal. Unlike traditional sequencing, which "blends" a tissue sample to see what genes are active, spatial transcriptomics allows researchers to see where those genes are active, providing a literal map of the battlefield within the tumor.
Implications for Precision Medicine and Future Therapies
The identification of periostin as a key facilitator of early spread opens the door to "precision medicine"—a shift away from generic chemotherapy toward treatments tailored to the molecular profile of a specific tumor.
Researchers believe that by targeting periostin or the stellate cells that produce it, they can disrupt the "highway" the cancer uses to spread. Clinical trials are already underway in other fields of oncology, such as breast and intestinal cancers, testing monoclonal antibodies designed to block periostin activity. The success of these trials could potentially be translated to pancreatic cancer treatment.
"If we can develop drugs that block these stellate cells or neutralize periostin, we may have the tools to prevent the tumor from acquiring this invasive capacity so early in the disease’s progression," said Dr. Uson. Such a therapy would not only potentially extend life expectancy but could also significantly improve the quality of life by reducing the nerve-related pain that plagues patients.
A New Frontier in Oncology
The study’s findings suggest that the future of oncology lies in treating the "ecosystem" of the tumor rather than just the cancer cells themselves. By addressing the supportive structures—the nerves, the stroma, and the extracellular matrix—doctors may finally be able to break the "fortress" that makes pancreatic cancer so deadly.
The researchers at CRID and the University of São Paulo are now looking toward the next phase of their work, which involves testing periostin inhibitors in laboratory models to see if the spread can be halted before it reaches the nervous system.
"Precision medicine is advancing rapidly," concluded Dr. Uson. "In the coming years, we will treat patients based on specific genomic and molecular changes. This research is a significant step toward that future, providing a roadmap for therapies that can act before the invasion begins."
As the global medical community continues to grapple with the rising incidence of pancreatic cancer, the work coming out of Brazil provides a vital piece of the puzzle. By shining a light on the hidden pathways of early metastasis, these researchers have provided a new glimmer of hope for a diagnosis that has, for too long, been considered a certain death sentence.